Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma

Pharmacotherapy

Volumn 17, Issue 1 SUPPL., 1997, Pages

  Drazen, Jeffrey M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; MONTELUKAST; SALBUTAMOL; TOMELUKAST; ZAFIRLUKAST; ZILEUTON;

AIRWAY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MAJOR CLINICAL STUDY; PATHOGENESIS; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

ARACHIDONATE 5-LIPOXYGENASE; ASTHMA; BRONCHOCONSTRICTION; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; LIPOXYGENASE INHIBITORS;

EID: 0031037332     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Laitinen A, Laitinen LA. Cellular infiltrates in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1991;143:1159-60.
2. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033-9.
3. Galli SJ. New concepts about the mast cell. N Engl J Med 1993;328:257-65.
4. 2 in inflammation. Adv Exp Med Biol 1990;275:103-13.
5. Kaiser E, Chiba P, Zaky K. Phospholipases in biology and medicine. Clin Biochem 1990;23:349-70.
6. Dennis EA, Rhe SG, Billah MM, Hannun YA. Role of phospholipase in generating lipid second messengers in signal transduction. FASEB J 1991;5:2068-77.
7. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-75.
8. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987;237:1171-6.
9. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990;323:645-55.
10. Woods JW, Evans JF, Ethier D, et al. 5-Lipoxygenase and 5-lipoxygenase activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med 1993;178:1935-46.
11. Miller DK, Gillard JW, Vickers PJ, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990;343:278-81.
12. Dixon RA, Diehl RE, Opas E, et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990;343:282-4.
13. Abramovitz M, Wong E, Cox ME, Richardson CD, Li C, Vickers PJ. 5-Lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur J Biochem 1993;215:105-11.
14. Reid GK, Kargman S, Vickers PJ, et al. Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis. J Biol Chem 1990;265:19818-23.
15. Mancini JA, Abramovitz M, Cox ME, et al. 5-Lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett 1993;31(8):277-81.
16. 4. Proc Natl Acad Sci USA 1994;91:7663-7.
17. 4 by human eosinophils. J Biol Chem 1989; 264: 12885-9.
18. Drazen JM, Austen KF, Lewis RA, et al. Comparative airway and vascular activity of leukotriene C-1 and D in vivo and in vitro. Proc Natl Acad Sci USA 1980;77:4345-58.
19. 4 increase the release of mucus from human airways. Am Rev Respir Dis 1982;126:449-51.
20. Drazen JM. Comparative contractile responses to sulfidopeptide leukotrienes in normal and asthmatic human subjects. Ann NY Acad Sci 1988;524:289-97.
21. 4 hydrolase cDNA. Biochem Biophys Res Commun 1991;176:1516-24.
22. 4 hydrolase. Am J Respir Cell Mol Biol 1994;11:615-24.
23. Coleman RA, Eglen RM, Jones RL, et al. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv Prost Thrombox Leuko Res 1995;23:283-5.
24. Weller PF. The immunobiology of eosinophils. N Engl J Med 1991;324:1110-18.
25. Eggleston PA, Kagey-Sobotka A, Proud D, Adkinson NF, Lichenstein LM. Disassociation of the release of histamine and arachidonic acid metabolites from osmotically activated basophils and mast cells. Am Rev Respir Dis 1990;141:960-4.
26. Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980;288:484-6.
27. Weiss JW, Drazen JM, McFadden ER, et al. Airway constriction in normal humans produced by inhalation of leukotriene D: potency, time course and effect of aspirin therapy. JAMA 1983;249:2814-17.
28. 4 and histamine in normal human subjects. Thorax 1984;39:500-4.
29. Taylor GW, Taylor I, Black P, et al. Urinary leukotriene E(4) after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989;1:584-8.
30. 4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992;146:104-8.
31. Asano K, Lilly CM, O'Donnell WJ, et al. Diurnal variation of urinary leukotriene E(4) and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. J Allergy Clin Immunol 1995;96:643-51.
32. Israel E, Juniper EF, Callaghan JT, et al. Effect of a leukotriene antagonist, LY 171883, on cold air-induced broncho-constriction in asthmatics. Am Rev Respir Dis 1989;140: 1348-53.
33. Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990;323:1740-4.
34. 4-receptor antagonist. N Engl J Med 1990;323:1736-9.
35. 4 receptor antagonist. Am Rev Respir Dis 1992;145:746-9.
36. Makker HK, Lau LC, Thomson HW, Binks SM, Holgate ST. The protective effect of inhaled leukotriene-D(4) receptor antagonist ICI-204,219 against exercise-induced asthma. Am Rev Respir Dis 1993;147:1413-18.
37. 4-antagonist. N Engl J Med 1990;323:1736-9.
38. Israel ER, Dermakarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990;323:1740-4.
39. Robuschi M, Riva E, Fuccella LM, et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). Am Rev Respir Dis 1992;145:1285-8.
40. Dahlen SE, Dahlen B, Eliasson E, et al. Inhibition of allergic bronchoconstriction in asthmatics by the leukotriene-antagonist ICI-204,219. Adv Prostaglandin Thromboxane Leukot Res 1991;21A:461-4.
41. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337:690-4.
42. Findlay SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992;89:1040-5.
43. 4 receptor antagonist, MK-571. Ann N Y Acad Sci 1991;629:436.
44. Hui KP, Taylor IK, Taylor GW, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991;46:184-9.
45. Nasser SM, Bell GS, Hawksworth RJ, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. Thorax 1994;49:743-8.
46. 4 receptor antagonist ICI-204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993;147:1431-5.
47. Friedman BS, Bel EH, Buntinx A, et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993;147:839-44.
48. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993;148:1447-51.
49. 4, and histamine in asthmatics. Am Rev Respir Dis 1992;146:96-103.
50. Christie L, Lee TH. The effects of SKF104353 on aspirin-induced asthma. Am Rev Respir Dis 1991;144:957-8.
51. Nasser SM, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 1994;49:749-56.
52. Knapp HR, Sladek K, Fitzgerald GA. Increased excretion of leukotriene E4 during aspirin-induced asthma. J Lab Clin Med 1992;119:48-51.
53. Schellenberg RR, Walker B. Platelet-dependent contraction of human bronchus by platelet-activating factor. J Allergy Clin Immunol 1983;71:154.
54. 4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1993;147:215-7.
55. 4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis 1989;140: 1336-1339.
56. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med 1993;119:1059-66.
57. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-23.
58. Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. JAMA 1996;275(12):931-6.